目的

通过乳腺癌血清蛋白质芯片检测来分析乳腺癌的预后差异，寻找新的判断预后的指标，以期为临床治疗方案的选择提供有价值的依据。

方法

采用美国Ciphergen公司生产的蛋白质芯片阅读机，选择IMAC-3和WCX-2两种芯片，对64例乳腺癌患者血清进行研究。64例乳腺癌患者全部随访5年，死亡13例。采用Ciphergen proteinchip3.0软件分析乳腺癌患者血清的蛋白质谱。将13例死亡患者的蛋白质图谱与其余患者的进行比对，差异比较采用t检验，P﹤0.05为有统计学意义。

结果

在WCX-2蛋白芯片，有2个位点，相对分子质量（M_r）分别为9405和6424的位置，死亡与生存乳腺癌患者的血清蛋白峰表达有差异，在M_r9405的位置，生存乳腺癌患者低表达；在M_r6424的位置，生存乳腺癌患者高表达，敏感性为76.9%～84.6%，特异性为76.4%～80.3%。在IMAC-3蛋白芯片，发现有2个位点，M_r分别为4643和5910的位置，死亡与生存的乳腺癌患者血清蛋白峰表达有差异，生存乳腺癌患者高表达，敏感性为61.5%～76.9%，特异性为68.6%～74.5%。

结论

死亡与生存乳腺癌患者血清蛋白峰表达存在差异，有可能成为新的判断乳腺癌预后的指标。

Objective

To find new biomarkers that can estimate the prognosis of breast cancer patients，for the patients who have the similar staging and accept same treatment get different treatment results.

Methods

Protein expression differences of serum samples of 64 breast cancer patients were analyzed with IMAC-3 and WCX-2 Ciphergen Protein Chip Arrays.Five-year follow-up of all the 64 breast cancer patients showed 13 patients died.The protein atlas of the 13 dead patients was compared with that of the other patients.

Results

On WCX-2 chip，a panel of two proteins（M_r9405 and M_r6424）was selected based on their collective contribution to the optimal separation between the dead patients and alive patients after 5-year follow-up.On M_r9405 site survived breast cancer patients had low expression，on M_r6424 site survived breast cancer patients had high expression，with sensitivity of 76.9%-84.6%and specificity of 76.4%-80.3%.On IMAC-3 chip，another two proteins（M_r4643 and M_r5910）had the ability to distinguish between the dead patients and alive patients after 5-year follow-up.Survived breast cancer patients had high expression，with sensitivity of 61.5%～76.9%and specificity of 68.6%～74.5%.

Conclusion

Protein expression in dead patients after 5-year follow-up is different from that of alive patients after 5-year follow-up，and those proteins with different expressions can be used as new biomarkers to predict breast cancer prognosis.